Estimates Revisions Capricor Therapeutics, Inc.
Stocks
CAPR
US14070B3096
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 09/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 8.640 USD | -4.64% |
|
-12.64% | -70.06% |
| 09-01 | Capricor Therapeutics Shares Rise After Piper Sandler Upgrade | MT |
| 09-01 | Piper Sandler Upgrades Capricor Therapeutics to Overweight From Neutral, Adjusts PT to $25 From $2 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- CAPR Stock
- Consensus Capricor Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
